Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7866072 | 0.94 | CTSS (0.61) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL6875218 | 0.93 | ADRB3 (0.57) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL10060798 | 0.93 | ADRB3 (0.57) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL6880425 | 0.93 | ADRB3 (0.56) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL16508689 | 0.93 | ADRB3 (0.56) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL6876461 | 0.93 | ADRB3 (0.56) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL6877299 | 0.93 | ADRB3 (0.56) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL6880412 | 0.91 | ADRB3 (0.55) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL6877886 | 0.91 | ADRB3 (0.55) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL10157231 | 0.91 | ADRB3 (0.68) | ADRB3ADRA2BADRA2CCYP3A4CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2012054874-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | ADRB3 3929/4885ADRA2B 3554/4885ADRA2C 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.